Capricor is working toward a potential FDA decision by Aug. 22, making the next two months a key regulatory stretch for CAPR investors.
- Fresh filings showed CFO Anthony Bergmann and legal chief Karen Krasney sold about $1.46 million in shares on June 25.
- Both executives exercised 24,100 options at $3.18 and sold the shares at an average price of $30.38.
- Capricor’s DMD therapy, Deramiocel, is heading to an FDA panel review on July 29.
Shares of Capricor Therapeutics (CAPR) closed at a four-month low on Monday after new filings showed that senior executives sold nearly $1.5 million in shares, while the company prepares for a key FDA review of its Duchenne muscular dystrophy treatment.
CAPR stock slumped 10% on Monday to end at $23.8, logging its second straight session in the red, although it climbed a bit in extended trading.
Capricor Execs Sell $1.46M In Shares
Fresh filings from Monday showed that CFO Anthony Bergmann and EVP and General Counsel Karen Krasney each exercised 24,100 stock options at $3.18 per share and sold the same number of shares at a weighted-average price of $30.38.
Together, the executives sold 48,200 shares for about $1.46 million in gross proceeds. The filings said that the sales were made under 10b5-1 trading plans adopted in December 2025. After the transactions, Bergmann owned 11,223 shares of the company and retained 91,980 stock options, while Krasney owned 30,547 shares and retained 31,261 options.
The insider filings come as Capricor’s lead therapy, Deramiocel, heads toward a major regulatory milestone. Last week, Capricor said that the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee planned to meet on July 29 to discuss the company’s Biologics License Application (BLA) seeking approval of Deramiocel for Duchenne muscular dystrophy (DMD).
The company said that the application is supported by its Phase 2 Hope-2 trial, long-term Hope-2 open-label extension data and positive Phase 3 Hope-3 results. Capricor is working toward a potential FDA decision ahead of its Aug. 22 PDUFA target action date.
Capricor Points To Positive Trial Data
Capricor also reported positive five-year results from its ongoing Hope-2 open-label extension study last week. Among the nine patients who stayed in the study, Deramiocel appeared to slow the worsening of DMD over five years. Patients treated with Deramiocel had an average decline of less than 5 points in upper-limb function over five years. By comparison, a matched group of DMD patients receiving standard care would be expected to decline by about 12 points over the same period.
The company also said that patients’ heart function remained stable across the five-year period, while a comparable outside group would have been expected to show a decline. Separately, Capricor said its Phase 3 Hope-3 trial met its primary endpoint, a key cardiac endpoint and all other Type I error-controlled secondary endpoints.
How Do Retail Traders Feel About CAPR?
On Stocktwits, retail sentiment for CAPR jumped to ‘extremely bullish’ from ‘bullish’ levels a day ago amid a 592% surge in 24-hour message volumes.
CAPR stock has jumped 113% over the past year.
For updates and corrections, email newsroom[at]stocktwits[dot]com.<